PDS Biotechnology/PDSB

$2.64

-8.79%
-
1D1W1MYTD1YMAX

About PDS Biotechnology

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

Ticker

PDSB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Frank Bedu-Addo

Employees

25

Headquarters

Princeton, United States

PDSB Metrics

BasicAdvanced
$99.77M
Market cap
-
P/E ratio
-$1.39
EPS
1.80
Beta
-
Dividend rate
$99.77M
1.79897
$10.27
$2.68
923.76K
4.333
75.118
91.277
-33.04%
-62.97%
-122.46%
-76.04%
3.445
3.818
4.23%

What the Analysts think about PDSB

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
445.45% upside
High $21.00
Low $5.00
$2.64
Current price
$14.40
Average price target

PDSB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-10.8M
-0%
Profit margin
0%
-

PDSB Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.2%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.32
-$0.37
-$0.35
-$0.35
-
Expected
-$0.31
-$0.35
-$0.45
-$0.44
-$0.37
Surprise
4.67%
6.58%
-21.47%
-20.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for PDS Biotechnology stock?

PDS Biotechnology (PDSB) has a market cap of $106.37M as of April 20, 2024.

What is the P/E ratio for PDS Biotechnology stock?

The price to earnings (P/E) ratio for PDS Biotechnology (PDSB) stock is 0 as of April 20, 2024.

Does PDS Biotechnology stock pay dividends?

No, PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next PDS Biotechnology dividend payment date?

PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders.

What is the beta indicator for PDS Biotechnology?

PDS Biotechnology (PDSB) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the PDS Biotechnology stock price target?

The target price for PDS Biotechnology (PDSB) stock is $14.4, which is 445.45% above the current price of $2.64. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell PDS Biotechnology stock

Buy or sell PDS Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing